Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer.

about

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer.

Item

http://www.wikidata.org/entity/Q46090703

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer.

@en

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer.

@nl

type

Item

label

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer.

@en

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer.

@nl

prefLabel

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer.

@en

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer.

@nl

P1476

Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer

@en

P2093

Alexander N. Shoushtari

http://www.w3.org/2001/XMLSchema#string

Anthony Daniyan

http://www.w3.org/2001/XMLSchema#string

Ariel Bulua Bourla

http://www.w3.org/2001/XMLSchema#string

Claire Friedman

http://www.w3.org/2001/XMLSchema#string

Danny N. Khalil

http://www.w3.org/2001/XMLSchema#string

David B. Page

http://www.w3.org/2001/XMLSchema#string

Eric Smith

http://www.w3.org/2001/XMLSchema#string

Jarushka Naidoo

http://www.w3.org/2001/XMLSchema#string

Margaret K. Callahan

http://www.w3.org/2001/XMLSchema#string

Melody Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Suppression, subversion and escape: the role of regulatory T cells in cancer progression

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Nivolumab plus ipilimumab in advanced melanoma.

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

The blockade of immune checkpoints in cancer immunotherapy

P31

scholarly article

P356

10.1186/S40425-015-0072-2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P921

immunotherapy

P932

4469248

http://www.w3.org/2001/XMLSchema#string